1	Serum protein biomarkers for degenerative cervical myelopathy: a prospective pilot study
2	
3	Aditya Vedantam, MD ¹ , Mahmudur Rahman, MS, Sakib Salam, MS ¹ , Anjishnu Banerjee, Ph.D. ² , Kajana
4	Satkunendrarajah, Ph.D. ¹ , Matthew D. Budde, Ph.D. ¹ , & Timothy B. Meier, Ph.D. ¹
5	
6	¹ Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI
7	² Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
8	
9	
10	Corresponding Author:
11	Aditya Vedantam, MD
12	Associate Professor of Neurosurgery
13	Medical College of Wisconsin
14	avedantam@mcw.edu
15	
16	
17	
18	
19	
20	
21 22	
22	
23 24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	

35 Abstract

36

37 Introduction

38 Diagnosis of degenerative cervical myelopathy (DCM) is primarily based on clinical evaluation and evidence 39 of cervical spinal cord compression on conventional MRI. However, delays in diagnosis are common in 40 DCM and there is a need for additional objective assessments of spinal cord structure and function. Serum 41 proteins are increasingly being used as biomarkers for neurological disorders and are promising targets for 42 biomarker discovery in DCM. The objective of this study was to profile serum protein biomarkers in DCM 43 and determine if serum proteins can aid diagnosis and prognosis in DCM.

44

45 Methods

46 Patients with a clinical diagnosis of DCM and scheduled to undergo decompressive surgery were

47 prospectively enrolled from July 2022 to August 2023. Serum was obtained prior to surgery and at 3 months

48 after surgery. Serum neuronal and inflammatory proteins were quantified using ultrasensitive single-

49 molecular array technology. Serum biomarker concentrations were compared between DCM patients and

age- and sex-matched healthy controls. Robust logistic regression was used to determine the panel of serum

51 biomarkers that best differentiated DCM and controls. Serum biomarkers were also related to pre- and post-

52 surgical functional measurements using linear regression.

53

54 **Results**

Twenty DCM patients (median age 70 years, 10 females) and 10 healthy controls (median age 65 years, 5
females) were enrolled. Pre-surgical NfL (30.2 vs 11.2 pg/ml, p=0.01) and IL-6 (2.9 vs 1.2, p=0.003) was
significantly higher in DCM patients compared to controls. Pre-surgical NfL, IL-6 and BDNF best
differentiated DCM and controls (p<0.001). At 3 months after surgery, significant increase in serum BDNF

59 (p=0.001), AB-42 (p=0.042) and TNFa (p=0.007) were noted. Pre-surgical serum NfL was significantly

60 associated improvement in pinch strength after surgery (p < 0.05). Inflammatory biomarkers were linked to

61 improvement in the neck pain-related disability and upper limb function assessed by the QuickDASH.

62

63 Conclusion

64 A pre-surgical serum panel of NfL, IL-6 and BDNF may aid in the diagnosis of DCM. Serum NfL is

65 elevated in DCM and is associated with improvement in post-surgical objective measures of upper limb

66 function. Pre-surgical serum neuronal and inflammatory biomarkers predict early post-surgical functional

- 67 outcomes in DCM.
- 68

69 Introduction

70 Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord injury 71 worldwide¹ with an estimated prevalence of 605 per million in North America.² The pathophysiology of 72 DCM is characterized by chronic spinal cord compression, spinal cord ischemia, neuroinflammation 73 ultimately leading to axonal injury and demyelination.² Many of the early symptoms of DCM are subtle, 74 difficult to confirm on clinical examination, and may be confounded by co-morbid conditions. This can lead 75 to a delay in diagnosis and surgical intervention, which contributes to poorer recovery of neurological 76 function. Surgical decompression of the cervical spinal cord is the primary treatment for DCM and surgical 77 decision-making is primarily based on the clinical examination findings and evidence of cervical spinal cord 78 compression on conventional MRI. The degree of spinal cord compression on conventional MRI, however, correlates poorly with neurological dysfunction in myelopathy,^{3,4} yet this remains a major driver behind the 79 decision to offer surgery.⁵ To better identify patients who will benefit from surgery, there is a need for 80 81 additional objective assessments of spinal cord structure and function. 82 83 Serum proteins are promising targets for biomarker discovery in DCM due to ease of obtaining 84 biospecimens, potential for repeated sampling and objective quantification. Serum biomarkers such as NfL⁶ and GFAP⁷ are elevated in in spinal cord pathologies such as traumatic spinal cord injury,⁸ multiple 85 sclerosis,⁹ amyotrophic lateral sclerosis¹⁰ and transverse myelitis,¹¹ highlighting a close relationship between 86

87 serum biomarkers and spinal cord damage. Since DCM is a form of chronic spinal cord injury, which
88 includes spinal cord ischemia and neuroinflammation,¹² it is expected that serum biomarkers will reflect
89 ongoing spinal cord damage as well as recovery of neurological function after surgery.

90

91 The aim of this pilot study was to profile serum biomarkers for DCM before and after surgical

92 decompression and determine whether these biomarkers are associated with pre-surgical and early post-93 surgical function.

94

95 Methods

96 Patients with a clinical diagnosis of DCM and scheduled to undergo decompressive surgery were enrolled 97 prospectively from July 2022 to August 2023. DCM patients (aged 18-90 years) with one or more signs of 98 symptoms of cervical myelopathy in addition to evidence of cervical spinal cord compression on MRI were 99 included. We excluded patients with trauma, syringomyelia, cord hemorrhage, tumor, pregnancy and other 100 neurological or muscular diseases that could explain their symptoms as well as those with a history of prior 101 cervical spine surgery. Age- and sex-matched healthy controls with no history of neck symptoms or

- neurological or muscular diseases were also enrolled. Institutional review board approval was obtained, andall participants provided written informed consent.
- 104

105 *Serum sampling*

Blood was drawn via venipuncture for both DCM patients and controls. For DCM patients, blood was drawn
before surgery and at 3 months after surgery. Samples were allowed to clot upright 30-60 minutes prior to
centrifugation at 1300-1500x g for 10 minutes in a swing bucket centrifuge at room temperature, after which
the serum was collected. Samples were stored at -80 C in 0.5ml aliquots prior to biomarker quantification.

110

111 Biomarker Quantification

Biomarker concentrations were quantified by Quanterix (Billerica, MA) using manufacturer protocols and 112 113 reagents. This proprietary ultrasensitive single-molecular array (Simoa) technology has previously been used in prior biomarker studies.⁸ For the purposes of this study, we quantified the concentrations of BDNF 114 115 (product code: 102039), NF-L, GFAP, AB40, AB42 (N4PE kit, product code: 103670), and Tau (product 116 code: 105168). Inflammatory biomarkers were quantified using the Simoa CorPlex Human Cytokine Panel 117 for IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22 and TNFa. All testing was 118 performed in duplicate and the average concentration with dilution correction was used for statistical 119 analysis.

120

121 *Functional Testing*

122 All DCM participants underwent pre-surgical and post-surgical (at 3 months after surgery) functional testing. 123 Functional measures included the modified Japanese Orthopedic Association scale (mJOA) which is a 124 myelopathy-specific symptom survey. Other symptom surveys included the Neck Disability Index (NDI), 125 which measures how neck pain affects daily living and the QuickDASH, which surveys upper limb 126 dysfunction during activities of daily living. Balance was assessed using the Berg Balance Scale (BBS). 127 Quality of life was quantified using the Short Form 36 Physical Component Score version 2 (SF36 PCS). 128 Objective measures of upper limb function included handgrip strength (measured using Jamar Plus Hand 129 Dynamometer) and pinch strength (measured using Jamar Digital Pinch Gauge). Handgrip and pinch 130 strength were recorded as the average of three trials for each hand and the mean between right and left hands 131 was used for analysis.

132

133 Statistical analysis

134 Biomarker concentrations were compared between DCM and control groups using unpaired t-tests (non-

parametric Wilcoxon rank sum tests if either normality or homogeneity of variance was violated); similarly,

136 DCM pre -and post-surgery measures were compared using paired t-tests (non-parametric Wilcoxon signed 137 rank test whenever assumptions of normality or homogeneity of variance violated). For continuous 138 outcomes, linear regression was used to test associations between biomarkers and pre-surgery function or 139 biomarkers and change in function after surgery. Change in function after surgery was calculated as the 140 difference in functional score between pre-surgery and post-surgery time points. Robust logistic regression with Huber type regularized estimators¹³ was performed to determine which biomarkers best differentiated 141 142 DCM and controls. Stepwise methods were used to find the best set of predictor variables for each regression 143 model. Estimates for the area under the ROC curves (AUC, c-statistic) were used to measure diagnostic 144 ability of biomarkers for DCM, with confidence interval being reported for each reported c-statistic. 145 Statistical analysis was performed using R version 4.4.0 and SPSS version 23. 146 147 **Results** 148 Twenty participants with DCM and 10 healthy controls were enrolled. All DCM participants underwent 149 surgery for DCM and had 3 month follow-up. Baseline demographic data are shown in **Table 1**. There were 150 no significant differences in age (p=0.18) and sex (p>0.9) between DCM participants and controls. 151 152 Serum concentrations of IFN-gamma, IL-1beta, IL-4, IL-5 and IL-12p70 had multiple values (greater than 153 50%) below the lower limit of quantification and were not included in the analysis. For TNFa, eight out of 50 154 samples were below lower limit of quantification and extrapolated lower limit values were used. For one pre-155 surgical sample, TNFa was below the limit of detection and was removed from the analysis. For one pre-156 surgical sample, NfL could not be quantified due to technical issues during processing. Pre- and post-surgical 157 functional measures are shown in Table 2. Pre-surgical grip and pinch strength were not available for two

159

subjects.

158

160 Pre-surgical serum biomarkers

161 Serum NfL (30.2 vs 11.2 pg/ml, p=0.01) and IL-6 (2.9 vs 1.2 pg/ml, p=0.003) were significantly higher in 162 pre-surgical plasma from DCM participants as compared to healthy controls (Figure 1). Serum GFAP (132) 163 vs 103 pg/ml, p=0.22) was also higher in DCM participants, however, the difference was not statistically 164 significant. No significant difference in concentration of other serum protein biomarkers were noted (**Table** 165 1). Using Huber type estimators in a robust logistic regression controlling for age, the serum biomarker panel 166 that best differentiated DCM and healthy controls included NfL, IL-6 and BDNF (p<0.001). ROC curves 167 analysis for serum NfL (AUC 0.79, 95% CI 0.62-0.96), IL-6 (AUC 0.84, 95% CI 0.65-1.00) and BDNF 168 (AUC 0.35, 95% CI 0.14-0.57) are shown in Figure 2. The combined panel of NfL, IL-6, and BDNF

169 demonstrated an AUC = 0.83, 95% CI 0.68-0.98.

170

171 Association between pre-surgical serum biomarkers and pre-surgical function

- No significant associations between pre-surgical biomarkers and mJOA, NDI or QuickDASH were noted
 (Table 3). Pre-surgical serum IL-22 was significantly linked to the pre-surgical balance as measured by the
 BBS score. Multiple serum biomarkers (GFAP, BDNF, AB40, AB42, IL-6, IL-8, IL-22) were significantly
- associated with pre-surgical quality of life as measured by SF36 PCS.
- 176

177 Change in serum biomarkers at 3 months after surgery for DCM

- Statistically significant increases in BDNF (p=0.001), AB-42 (p=0.042) and TNFa (p=0.007) were noted at 3
 months after surgery (Figure 3). Although serum NfL decreased (p=0.23) after surgery, the difference was
 not statistically significant. No significant change was noted in any of the other serum biomarkers after
 surgery.
- 182

183 Association between pre-surgical biomarkers and change in function after surgery

- 184 Pre-surgical serum AB-40 (p=0.02) was significantly associated with improvement in mJOA at 3 months
- 185 after surgery. Multiple serum biomarkers predicted improvement in NDI and QuickDASH at 3 months after
- 186 surgery (Table 4). Pre-surgical IL-10 predicted improvements in upper limb function as measured by
- 187 QuickDASH and quality of life measured by SF36 PCS. Pre-surgical NfL was significantly (p=0.03)
- 188 associated with improvement in mean pinch strength at follow-up.
- 189

190 Discussion

Objective measures of spinal cord structure and function are needed to improve surgical selection for DCM and serum biomarkers show promise in fulfilling this clinical need. This pilot study evaluated a panel of serum biomarkers for diagnosis and prognosis in DCM. Serum NfL, IL-6 and BDNF were associated with a diagnosis of DCM. Serum NfL was strongly associated with baseline and follow-up quantitative hand function. Serum BDNF, AB-42 and TNFa showed significant increases in concentration at 3 months after surgery. Pre-surgical inflammatory and neuronal serum biomarkers were linked to improvements in postsurgical symptom scores.

198

199 Compared to healthy controls, DCM was associated with higher serum NfL and IL-6 concentrations. NfL is

a marker of cytoskeletal neuronal injury, and prior studies have shown the pre-surgical CSF levels of NfL are

- 201 elevated in DCM¹⁴ and can predict post-surgical outcome.¹⁵ Serum NfL levels show strong linear
- 202 correlations to levels in spinal CSF indicating a spinal cord source for the NfL and potential for biomarker
- 203 detection using blood samples after spinal cord injury.⁸ Elevated levels of serum NfL have been observed in

multiple sclerosis,¹⁶ amyotrophic lateral sclerosis¹⁰ as well as after acute spinal cord injury⁸ highlighting its 204 205 role as a biomarker of active spinal cord damage. While elevated serum NfL levels are not specific to DCM, 206 NfL levels can support the diagnosis of DCM in patients with high clinical suspicion. NfL levels did 207 decrease at 3 months after surgery (29.1% decrease in median NfL levels), but the difference was not 208 statistically significant. Studies in multiple sclerosis show a greater than 35% reduction in NfL levels at 6 months after starting treatment and further reduction at 24 months⁹ suggesting that NfL levels may continue 209 210 to decrease at longer follow-up after surgery for DCM. IL-6 is produced by immune cells in the peripheral 211 blood as well as by neurons in the CNS, and is known to be elevated in Parkinson's disease and multiple sclerosis.¹⁷ It is a pleiotropic cytokine with pro-inflammatory and neuro-regenerative effects with evidence 212 for promoting recovery after experimental spinal cord injury.¹⁸ In DCM, elevated levels of IL-6 have been 213 measured in the CSF,¹⁹ and serum IL-6 has been shown to be elevated in patients with degenerative disk 214 disease.²⁰ At 3 months after surgery, IL-6 concentrations remained persistently higher than controls (p=0.01). 215 Together, elevated levels of serum IL-6 prior to surgery may be linked to active neurodegeneration as well as 216 217 disk degeneration, which are seen commonly in DCM. The panel of serum biomarkers (NfL, IL-6 and BDNF) best differentiated DCM and controls. BDNF plays a role in brain plasticity, which is seen in DCM 218 prior to surgery²¹ due to the chronic spinal cord compression. Val66Met mutations in the BDNF gene have 219 been associated with poorer baseline function in DCM suggesting a role for BDNF in the pathophysiology of 220 221 the disease.²² Together, this panel of serum biomarkers captures structural neuronal injury, inflammation and 222 neuronal plasticity, which play a role in the pathophysiology of DCM.

223

224 There was a significant increase in serum neuronal (BDNF, AB-42) and inflammatory biomarkers (TNFa) at 225 3 months after surgery when comparing pre- and post-surgical samples in DCM patients. The increase in 226 BDNF could be explained by its role in plasticity and neurological recovery, as shown in experimental spinal cord injury.²³ In this study we noted a small but significant increase in AB-42 concentration after surgery. 227 Amyloid breakdown proteins such as AB-42 are lower in CSF in DCM patients compared to controls.¹⁴ An 228 increase in blood²⁴ and CSF AB-42 levels²⁵ is seen after major surgery indicating an association between 229 230 surgical intervention and elevated plasma AB-42 concentration so it is unclear if our result is related to the 231 surgical intervention or neurological recovery. While TNFa concentrations in CSF in cervical myelopathy are low,^{19,26} prior studies have shown that TNFa contributes to neuroinflammation and blood spinal cord 232 barrier disruption that can persist in the chronic stages of DCM.²⁷ However, serum TNFa also increases after 233 234 major surgery,²⁸ which may explain the findings in this study.

235

Correlations between pre surgical biomarkers and baseline neurological function as measured by standardsymptoms scores were not robust. These findings are not entirely unexpected given the subjective nature of

these symptom scores as well as their limited granularity and range.^{29–31} Prior studies have shown that serum biomarkers are linked to more objective functional measures after spinal cord injury such as the ASIA grade.⁸ Higher pre-surgical NfL was associated with greater mean pre-surgical hand grip strength but the relationship was not statistically significant (p=0.09). Multiple neuronal and inflammatory biomarkers were linked to pre-surgical quality of life (SF36 PCS), which is not a disease-specific survey but could represent the effect of pain and disability. Inflammatory markers could be elevated due to pre-surgical pain, which is often present in these patients due to associated osteoarthritis of the cervical spine.

245

246 Several pre-surgical biomarkers were associated with early post-surgical function outcomes in this study. Pre-surgical serum NfL was positively associated with improvements in pinch strength, demonstrating the 247 248 link between neuronal injury and objective measures of neurological function. Objective markers of hand 249 function such as pinch strength are increasingly being used for DCM and show robust improvements after surgery.³² Serum NfL is elevated rapidly after acute spinal cord injury⁸ and CSF NfL is higher in patients 250 with shorter duration of symptoms.¹⁴ These findings suggest that NfL is associated with more recent axonal 251 injury. Higher pre-surgical NfL levels in serum and CSF are linked to improved outcomes in DCM.¹⁴ Higher 252 253 presurgical serum AB40 was the only biomarker to be significantly associated with improvement in mJOA 254 scores at 3 months. AB40 levels are elevated acutely after CNS injury and decrease in the chronic phase, 255 with higher acute CSF AB40 levels linked to neurological improvement in traumatic brain injury.³³ Higher 256 AB40 levels prior to surgery may indicate more acute injury with a higher potential for neurological 257 recovery. Improvement in NDI was associated with several pre-surgical neuronal as well as inflammatory 258 biomarkers indicating that changes in neck pain-related disability after surgery are linked to complex multi-259 system biological processes including inflammation. We found a similar finding with improvements in 260 QuickDASH, which is also a subjective symptom score that assess the impact of upper limb pain and 261 disability.

262

This pilot study is limited by a small sample size as well as short term outcome data. We chose a 3-month time-point after surgery for both functional measurements as well as blood biomarker testing since the maximum rate of improvement of neurological function for the majority of DCM patients occurs in the first 3 months after surgery.³⁴ However, we acknowledge that patients with severe myelopathy do have potential to show continued improvement from 3 to 12 months after surgery.³⁵ Although we excluded DCM participants with neurological conditions such as multiple sclerosis or prior ischemic strokes, other comorbidities may impact serum biomarker levels.

- The strength of this study is the prospective homogenous cohort of DCM participants with pre- and post-surgical serum biomarker quantification. While the majority of prior studies have focused on CSF biomarkers for DCM,^{14,15} the results of this study highlight the utility of serum biomarkers, which show greater potential for clinical adoption given ease of sampling. Serum biomarkers (NfL, IL-6 and BDNF) can potentially aid in diagnosis of mild DCM, where patients may not demonstrate physical signs of myelopathy. The inclusion of pre- and post-surgical functional measurements enabled identification of clinical correlates of serum biomarkers in DCM. Serum biomarkers show potential for prognostication of function after surgery in DCM, which is a critical need in the field. Since over 30% of DCM patients do not achieve the minimum clinically important difference for function after surgery.^{36,37} improved prognostication will improve surgical counseling and selection of patients for surgery. We intend to validate the results of this study using a larger sample size as well as extending the duration of follow up after surgery.

283 Conclusion

Serum proteins are promising objective diagnostic and prognostic biomarkers for DCM. If validated, these
 results suggest that serum biomarkers can help diagnose and identify DCM patients who will respond best to
 surgical intervention.

305 306 307	Re 1.	ferences New PW, Cripps RA, Bonne Lee B. Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository. Spinal Cord. 2014;52:97–109.
308 309	2.	Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative Cervical Myelopathy: Epidemiology, Genetics, and Pathogenesis. Spine. 2015;40:E675-693.
310 311	3.	Rhee JM, Heflin JA, Hamasaki T, Freedman B. Prevalence of physical signs in cervical myelopathy: a prospective, controlled study. Spine. 2009;34:890–895.
312 313 314	4.	Nagata K, Yoshimura N, Muraki S, et al. Prevalence of cervical cord compression and its association with physical performance in a population-based cohort in Japan: the Wakayama Spine Study. Spine. 2012;37:1892–1898.
315 316 317	5.	Hilton B, Tempest-Mitchell J, Davies BM, et al. Cord compression defined by MRI is the driving factor behind the decision to operate in Degenerative Cervical Myelopathy despite poor correlation with disease severity. PloS One. 2019;14:e0226020.
318 319	6.	Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020;7:2508–2523.
320 321	7.	Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158–172.
322 323 324	8.	Stukas S, Cooper J, Gill J, et al. Association of CSF and Serum Neurofilament Light and Glial Fibrillary Acidic Protein, Injury Severity, and Outcome in Spinal Cord Injury. Neurology. 2023;100:e1221– e1233.
325 326	9.	Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92:e1007–e1015.
327 328	10.	Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59–e69.
329 330	11.	Lee HL, Seok JM, Chung YH, et al. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis. Mult Scler Relat Disord. 2023;79:104957.

- 331 12. Fehlings MG, Skaf G. A review of the pathophysiology of cervical spondylotic myelopathy with insights
 332 for potential novel mechanisms drawn from traumatic spinal cord injury. Spine. 1998;23:2730–2737.
- 333 13. Cantoni E, Ronchetti E. A robust approach for skewed and heavy-tailed outcomes in the analysis of
 334 health care expenditures. J Health Econ. 2006;25:198–213.
- 14. Tsitsopoulos PP, Holmström U, Blennow K, Zetterberg H, Marklund N. Cerebrospinal fluid biomarkers
 of glial and axonal injury in cervical spondylotic myelopathy. J Neurosurg Spine. 2021;34:632–641.
- Tsitsopoulos PP, Mondello S, Holmström U, Marklund N. Cerebrospinal fluid biomarkers of white
 matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative
 cervical spondylotic myelopathy. Spine J Off J North Am Spine Soc. 2022;22:1848–1856.

340 16. Kapoor R, Smith KE, Allegretta M, et al. Serum neurofilament light as a biomarker in progressive
341 multiple sclerosis. Neurology. 2020;95:436–444.

- 342 17. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim
 343 Biophys Acta. 2016;1863:1218–1227.
- 344 18. Yang P, Wen H, Ou S, Cui J, Fan D. IL-6 promotes regeneration and functional recovery after cortical
 345 spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse
 346 formation. Exp Neurol. 2012;236:19–27.
- Nagashima H, Morio Y, Yamane K, Nanjo Y, Teshima R. Tumor necrosis factor-alpha, interleukin1beta, and interleukin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar
 radiculopathy. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res
 Soc. 2009;18:1946–1950.

20. Deng X, Zhao F, Kang B, Zhang X. Elevated interleukin-6 expression levels are associated with
 intervertebral disc degeneration. Exp Ther Med. Spandidos Publications; 2016;11:1425–1432.

- 21. Cronin AE, Detombe SA, Duggal CA, Duggal N, Bartha R. Spinal cord compression is associated with
 brain plasticity in degenerative cervical myelopathy. Brain Commun. 2021;3:fcab131.
- 355 22. Abode-Iyamah KO, Stoner KE, Grossbach AJ, et al. Effects of brain derived neurotrophic factor
 356 Val66Met polymorphism in patients with cervical spondylotic myelopathy. J Clin Neurosci Off J
 357 Neurosurg Soc Australas. 2016;24:117–121.

- 358 23. Weishaupt N, Blesch A, Fouad K. BDNF: the career of a multifaceted neurotrophin in spinal cord injury.
 359 Exp Neurol. 2012;238:254–264.
- 24. Požgain Z, Dulić G, Kondža G, et al. Is postoperative cognitive decline after cardiac surgery associated
 with plasma beta amyloid 1-42 levels? J Cardiothorac Surg. 2022;17:6.
- 362 25. Danielson M, Wiklund A, Granath F, et al. Association between cerebrospinal fluid biomarkers of
 363 neuronal injury or amyloidosis and cognitive decline after major surgery. Br J Anaesth. 2021;126:467–
 364 476.
- 365 26. Ito K, Matsuyama Y, Yukawa Y, Kato F, Ishiguro N. Analysis of interleukin-8, interleukin-10, and
 366 tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy.
 367 J Spinal Disord Tech. 2008;21:145–147.

368 27. Karadimas SK, Gatzounis G, Fehlings MG. Pathobiology of cervical spondylotic myelopathy. Eur Spine
 369 J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 2015;24 Suppl 2:132–
 370 138.

- 371 28. Baxevanis CN, Papilas K, Dedoussis GV, Pavlis T, Papamichail M. Abnormal cytokine serum levels
 372 correlate with impaired cellular immune responses after surgery. Clin Immunol Immunopathol.
 373 1994;71:82–88.
- 374 29. Kopjar B, Tetreault L, Kalsi-Ryan S, Fehlings M. Psychometric properties of the modified Japanese
 375 Orthopaedic Association scale in patients with cervical spondylotic myelopathy. Spine. 2015;40:E23376 28.
- 30. Martin AR, Jentzsch T, Wilson JRF, et al. Inter-rater Reliability of the Modified Japanese Orthopedic
 Association Score in Degenerative Cervical Myelopathy: A Cross-sectional Study. Spine.
 2021;46:1063–1069.
- 380 31. Kalsi-Ryan S, Singh A, Massicotte EM, et al. Ancillary outcome measures for assessment of individuals
 381 with cervical spondylotic myelopathy. Spine. 2013;38:S111-122.
- 382 32. Cole TS, Almefty KK, Godzik J, et al. Functional improvement in hand strength and dexterity after
 383 surgical treatment of cervical spondylotic myelopathy: a prospective quantitative study. J Neurosurg
 384 Spine. Epub 2020 Feb 7.:1–7.

- 385 33. Mondello S, Buki A, Barzo P, et al. CSF and plasma amyloid-β temporal profiles and relationships with
 and mortality after severe traumatic brain injury. Sci Rep. 2014;4:6446.
- 34. Berlin C, Marino AC, Mummaneni PV, et al. Determining the time frame of maximum clinical
 improvement in surgical decompression for cervical spondylotic myelopathy when stratified by
 preoperative myelopathy severity: a cervical Quality Outcomes Database study. J Neurosurg Spine.
 Epub 2022 Jun 17.:1–9.
- 35. Khan I, Archer KR, Wanner JP, et al. Trajectory of Improvement in Myelopathic Symptoms From 3 to
 12 Months Following Surgery for Degenerative Cervical Myelopathy. Neurosurgery. 2020;86:763–768.
- 393 36. Tetreault L, Wilson JR, Kotter MRN, et al. Predicting the minimum clinically important difference in
 394 patients undergoing surgery for the treatment of degenerative cervical myelopathy. Neurosurg Focus.
 395 2016;40:E14.
- 396 37. Evaniew N, Cadotte DW, Dea N, et al. Clinical predictors of achieving the minimal clinically important
 397 difference after surgery for cervical spondylotic myelopathy: an external validation study from the
 398 Canadian Spine Outcomes and Research Network. J Neurosurg Spine. Epub 2020 Apr 10.:1–9.

- -

416	Figure Legends
417	
418	Figure 1. Violin plots comparing serum biomarkers for DCM and healthy controls.
419	
420	Figure 2. ROC curve showing diagnostic accuracy for pre-surgical serum biomarkers for DCM
421	
422	Figure 3. Violin plots showing serum biomarkers pre-surgery and post-surgery for 20 DCM patients.
423	Outlying data from post-surgical IL-10 concentration (11.5 pg/ml) and TNFa concentration (147.7 pg/ml)
424	from one sample are not plotted
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
44 I 1/12	
443	
444	
445	
446	
447	
448	
449	
-	

450 Tables

451

452 **Table 1.** Demographic and biomarker data for DCM patients and controls.

453

DCM (n=20) Controls (n=10) **P-value** 70 (37-78) 65 (51-76) 0.18 Age in years (min-max) Sex (M/F) 10/10 5/5 >0.9 NfL 30.2 (7.2-62) 11.2 (10-22.5) 0.01* GFAP 132 (44.8-407) 103 (75.4-223) 0.21 **BDNF** 18729 (2206-35055) 22969.5 (6900-0.16 38084) 0.23(0.1-0.7)Tau 0.25 (0.2-0.5) 0.52 AB4064.9 (0-117) 67.8 (35.3-100) 0.86 **AB42** 4.6 (0-7.7) 4.9 (3.1-7.2) 0.69 IL-6 2.9 (1-8.4) 1.2(0.5-7.2)0.003* 19.5 (7.9-43.8) IL-8 17 (9.8-19.6) 0.26 IL-10 0.5(0.2-2.8)0.5(0.1-2.4)0.59 IL-22 0.8(0.2-3.7)0.5(0.2-3.6)0.32 TNFa 0.5(0-1.9)0.7(0.4-1)0.18

454 All biomarkers concentrations in median (minimum - maximum) pg/ml

455

*p<0.05

456

457

458

459

460 461

462

463

464

465

466

467

468

469

470

471

472

473

474 475

476

477

478

479

480

481

486 Table 2. Pre- and post-surgical functional measures for 20 DCM participants

	Pre-surgery	Post-surgery at 3	P-value	
		months		
mJOA	14 (11-17)	16 (11-18)	0.06	
NDI	28±17.2	19.6 ± 15.9	0.015*	
QuickDASH	40.8 ± 17.3	27.4 ± 17.8	0.001*	
BBS	52 (6-56)	54 (17-56)	0.06	
SF-36 PCS	36.5 ± 7.8	39.9± 9.3	0.042*	
Hand grip strength				
-Right	66.2 (37.2-152)	83.5 (53.5-172.3)	0.001*	
-Left	79.1±28.5	87.2 ± 26.6	0.004*	
Pinch strength				
-Right	9.8±3.9	10.8 ± 5.4	0.42	
-Left	10.5 ± 4.6	11.4±4.8	0.44	

489 ^Normal data is represented as means ± standard deviation and data not normally distributed are represented

490 as median (minimum-maximum)

- 491 *p<0.05

- Table 3. Significant associations between pre-surgical serum biomarker concentrations and pre-surgical function

Pre-surgical	Unstandardized co-	Standard Error	P-value
serum	efficient B (95%		
Biomarker	CI)		
None			
None			
None			
IL-22	-13.3 (-23.6, -2.9)	4.4	0.02
GFAP	-0.05 (-0.09, -0.02)	0.02	0.01
BDNF	0.001 (0,0.001)	0.0	0.003
AB40	0.21 (0.03,0.39)	0.08	0.03
AB42	-3.4 (-6.5, -0.33)	1.3	0.04
IL-6	4.5 (2.7, 6.2)	0.7	< 0.001
IL-8	-0.6 (-0.8, -0.3)	0.1	0.002
IL-22	-8.5 (-11.4, -5.5)	1.2	< 0.001
None			
None			
	Pre-surgical serum Biomarker None None IL-22 GFAP BDNF AB40 AB42 IL-6 IL-8 IL-22 None None	Pre-surgical serum Unstandardized co-efficient B (95% CI) Biomarker CI) None	Pre-surgical serum Unstandardized co- efficient B (95% Standard Error Biomarker CI)

Table 4. Significant associations between pre-surgical serum biomarker concentrations and change in function at 3 months after surgery

Functional measure	Pre-surgical	Unstandardized co-	Standard	P-value
	serum	efficient B (95% CI)	Error	
	Biomarker	`		
Change in				
functional measures				
mJOA	AB40	-0.18 (-0.3,-0.03)	0.06	0.02
NDI	NfL	0.4 (0.01,0.8)	0.2	0.046
	GFAP	-0.1 (-0.2,-0.001)	0.04	0.049
	BDNF	-0.001 (-0.002,0)	0.0	0.014
	IL-6	-8.1 (-12.9,-3.3)	2.0	0.005
	IL-10	17.5 (5.7,29.2)	4.9	0.01
	IL-22	14.3 (6.0-22.5)	3.5	0.005
	TNFa	24.8 (8.4, 41.3)	6.9	0.009
QuickDASH	BDNF	-0.002 (-0.002,-0.001)	0.0	< 0.001
	Tau	-47.4 (-78.9,-15.9)	13.3	0.009
	AB40	0.5 (0.2,0.8)	0.1	0.005
	IL-6	-6.5 (-9.5,-3.5)	1.3	0.001
	IL-8	0.6 (0.1, 1.1)	0.2	0.02
	IL-10	19.3 (11.9,26.6)	2.2	0.005
	IL-22	17.3 (0.9,33.8)	6.9	0.04
BBS	IL-22	9.9 (1.5,18.3)	3.6	0.03
SF36 PCS	IL-10	-7.5 (-14.8,-0.3)	3.1	0.04
Mean hand grip	None	<u> </u>		
strength		U		
Mean pinch	NfL	0.3 (0.04,0.6)	0.1	0.03
strength				





